ERBB2 and breast cancer: These results indicated that modified nanobody–HER2 binds original HER2 target well with sensitivity and specificity via PANAC conjugation, while introduction of the fluorescence dye allowed the nanobody conjugates for breast cancer imaging or diagnostics.